Quick Answer
TREACE MEDICAL CONCEPTS, INC. reported Research And Development Expense of $20.28 million for the year ending 2025.
- TREACE MEDICAL CONCEPTS, INC. showed a decrease of -1.5% in Research And Development Expense from 2024 to 2025.
- This data is from TREACE MEDICAL CONCEPTS, INC.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $1.43 million | Q2 2020: $982.0 thousand | Q3 2020: $1.51 million | Q1 2021: $1.87 million | Q2 2021: $2.42 million | Q3 2021: $2.54 million | Q1 2022: $3.05 million | Q2 2022: $2.98 million | Q3 2022: $3.80 million | Q1 2023: $3.41 million | Q2 2023: $3.53 million | Q3 2023: $4.35 million | Q1 2024: $5.26 million | Q2 2024: $5.16 million | Q3 2024: $4.96 million | Q1 2025: $5.56 million | Q2 2025: $5.50 million | Q3 2025: $4.68 million.
- Over the full 7 years of available data (2019 to 2025), TREACE MEDICAL CONCEPTS, INC.'s Research And Development Expense has grown by 300.0%.
- Historical annual values: Fiscal year 2025: $20.28 million | Fiscal year 2024: $20.59 million | Fiscal year 2023: $15.44 million | Fiscal year 2022: $13.58 million | Fiscal year 2021: $10.20 million | Fiscal year 2020: $5.85 million | Fiscal year 2019: $5.07 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: